Science · 2013 · 587 citations · 42 references
Social SciencesHealth PolicySocial PolicyHiv PreventionPopulation Health PolicyRural HealthAfrican Health StudiesAntiretroviral TherapyHiv EpidemiologyLife ExpectancyLife Expectancy ChangeOutcome ValuationAntiretroviral AccessAntiretroviral Therapy CoverageCo-investment DecisionsHiv ArtHiv PrevalenceLife Expectancy ValuationReal Investment DecisionsSocial Value Measurement
The scale‑up of antiretroviral therapy (ART) is expected to raise adult life expectancy in populations with high HIV prevalence. Using data from a population cohort of over 101,000 individuals in rural KwaZulu‑Natal, South Africa, we measured changes in adult life expectancy for 2000‑2011. Adult life expectancy rose from 49.2 years in 2003 to 60.5 years in 2011, an 11.3‑year gain, and the monetary value of these survival benefits far exceeds the cost of ART, underscoring its social value and informing investment decisions by individuals, governments, and donors.
The scale-up of antiretroviral therapy (ART) is expected to raise adult life expectancy in populations with high HIV prevalence. Using data from a population cohort of over 101,000 individuals in rural KwaZulu-Natal, South Africa, we measured changes in adult life expectancy for 2000-2011. In 2003, the year before ART became available in the public-sector health system, adult life expectancy was 49.2 years; by 2011, adult life expectancy had increased to 60.5 years--an 11.3-year gain. Based on standard monetary valuation of life, the survival benefits of ART far outweigh the costs of providing treatment in this community. These gains in adult life expectancy signify the social value of ART and have implications for the investment decisions of individuals, governments, and donors.
42
The Statistical Analysis of Failure Time Data.
Murray Aitkin, John D. Kalbfleisch, Ross L. Prentice · Biometrics · 1981 · 10K citations